Goldman Sachs Group Inc. lowered its position in CTI BioPharma Corp. (NASDAQ:CTIC) by 95.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,355 shares of the biopharmaceutical company’s stock after selling 1,086,600 shares during the period. Goldman Sachs Group Inc. owned 0.18% of CTI BioPharma Corp. worth $216,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CTIC. Segantii Capital Management Ltd purchased a new stake in CTI BioPharma Corp. during the first quarter worth $102,000. Acadian Asset Management LLC purchased a new stake in CTI BioPharma Corp. during the first quarter worth $181,000. Finally, Nine Chapters Capital Management LLC increased its stake in CTI BioPharma Corp. by 152.9% in the first quarter. Nine Chapters Capital Management LLC now owns 43,500 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 26,300 shares in the last quarter. 42.87% of the stock is owned by institutional investors.

CTI BioPharma Corp. (NASDAQ:CTIC) traded down 1.75% during midday trading on Tuesday, hitting $3.36. The stock had a trading volume of 5,671 shares. CTI BioPharma Corp. has a 52 week low of $2.70 and a 52 week high of $6.48. The stock’s market cap is $106.60 million. The company has a 50-day moving average price of $3.39 and a 200-day moving average price of $3.89.

CTI BioPharma Corp. (NASDAQ:CTIC) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.63. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. The business had revenue of $22.23 million for the quarter. Equities analysts expect that CTI BioPharma Corp. will post ($2.40) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/29/goldman-sachs-group-inc-cuts-stake-in-cti-biopharma-corp-ctic.html.

CTI BioPharma Corp. Company Profile

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Institutional Ownership by Quarter for CTI BioPharma Corp. (NASDAQ:CTIC)

Receive News & Stock Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related stocks with our FREE daily email newsletter.